{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:15:44Z","timestamp":1791292544614,"version":"4.1.0"},"reference-count":284,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1713,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.bbmt.2010.05.005","type":"journal-article","created":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T04:18:19Z","timestamp":1274761099000},"page":"1037-1069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies"],"prefix":"10.1016","volume":"16","author":[{"given":"Edwin P.","family":"Alyea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Moldrem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Przepiorka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Sadelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Riddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2010.05.005_bib1","unstructured":"Pavletic SZ, Kumar S, Mohty M, et\u00a0al. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the committee on the epidemiology and natural history of relapse following allogeneic cell transplantation. Biol Blood and Marrow Transplant. in press."},{"key":"10.1016\/j.bbmt.2010.05.005_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.bbmt.2010.03.002","volume":"16","author":"Cairo","year":"2010","journal-title":"Biol Blood Marow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bbmt.2010.02.005","volume":"16","author":"Miller","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib4","first-page":"2931","volume":"90","author":"Ferrant","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib5","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood.V78.3.838.838","article-title":"Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2","volume":"78","author":"Copelan","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib6","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V90.4.1410","article-title":"Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"90","author":"Sierra","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib7","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood.V76.9.1867.1867","article-title":"Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens","volume":"76","author":"Clift","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib8","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1182\/blood.V77.8.1660.1660","article-title":"Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens","volume":"77","author":"Clift","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bbmt.2005.12.029","article-title":"A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission","volume":"12","author":"Marks","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib10","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1365-2141.1996.4811022.x","article-title":"Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia","volume":"93","author":"Anderson","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib12","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib14","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","volume":"101","author":"Niederwieser","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib15","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.2005.04.569","article-title":"Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia","volume":"23","author":"Sorror","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib16","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/blood.V85.4.1122.bloodjournal8541122","article-title":"Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labelled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation","volume":"85","author":"Matthews","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V94.4.1237","article-title":"Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome","volume":"94","author":"Matthews","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib18","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood-2005-06-2317","article-title":"131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission","volume":"107","author":"Pagel","year":"2006","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.bbmt.2010.05.005_bib19","first-page":"S193","article-title":"Targeted radiotherapy using 131I-anti-CD45 antibody followed by allogeneic hematopoietic cell transplantation (HCT): the relationships among dosimetry, bone marrow uptake, and relapse","volume":"33","author":"Pagel","year":"2006","journal-title":"EurJ Nuclear Med Mol Imag"},{"key":"10.1016\/j.bbmt.2010.05.005_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.397.397","article-title":"131I-anti-CD45 antibody plus fludarabine, low-dose total body irradiation and peripheral blood stem cell infusion for elderly patients with advanced acute myeloid leukemia (aml) or high-risk myelodysplastic syndrome (MDS)","volume":"106","author":"Pagel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bbmt.2007.11.012","article-title":"Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders","volume":"14","author":"Laport","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.2005.03.1765","article-title":"Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors","volume":"24","author":"Hegenbart","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib23","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/asheducation-2007.1.435","article-title":"Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges","author":"Thomas","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2010.05.005_bib25","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib26","doi-asserted-by":"crossref","first-page":"76a","DOI":"10.1182\/blood-2008-05-158535","volume":"112","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib27","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib28","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib29","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMe068073","article-title":"Circumventing resistance to kinase-inhibitor therapy","volume":"354","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib30","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib31","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib32","doi-asserted-by":"crossref","first-page":"843a","DOI":"10.1182\/blood.V110.11.2869.2869","article-title":"Autologous stem cell transplantation following sequential chemotherapy and imatinib for adults with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia\u2014CALGB study 10001","volume":"110","author":"Wetzler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib33","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases","volume":"102","author":"Carter","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.05.005_bib34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm1003","article-title":"VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo","volume":"10","author":"Harrington","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib35","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/0008-5472.CAN-05-2788","article-title":"Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the\u00a0Aurora kinase inhibitor VX-680","volume":"66","author":"Young","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib36","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib37","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood-2006-02-005579","article-title":"Activation of a novel Bcr\/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells","volume":"109","author":"Bartholomeusz","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib38","first-page":"437","article-title":"Select high risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia (CLL): preliminary justification for risk-adapted therapy","volume":"24","author":"Byrd","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib39","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/j.seminoncol.2006.01.012","article-title":"Treatment of relapsed chronic lymphocytic leukemia: old and new therapies","volume":"33","author":"Byrd","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib41","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib42","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.leu.2403398","article-title":"A sustained activation of PI3K\/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells","volume":"18","author":"Cuni","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.05.005_bib43","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-07-4622","article-title":"Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models","volume":"14","author":"Shoemaker","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib44","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2008-02-137943","article-title":"Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia","volume":"113","author":"O'Brien","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/10428190009060327","article-title":"Relapse of leukemia and lymphoma after marrow transplant: a review of cases with extramedullary relapse","volume":"38","author":"Linn","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.05.005_bib47","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib48","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib49","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ajh.21253","article-title":"Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission","volume":"83","author":"Stone","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib50","doi-asserted-by":"crossref","first-page":"53a","DOI":"10.1182\/blood.V110.11.157.157","article-title":"Phase III trial of immunotherapy with recombinant interleukin-2 (rIL-2) versus observation in patients <60 with acute myeloid leukemia in first remission: preliminary results from CALGB19808","volume":"110","author":"Kolitz","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1083-8791(00)70052-8","article-title":"Autologous stem cell transplantation for acute myeloid leukemia in first remission","volume":"6","author":"Linker","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib52","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1200\/JCO.2008.17.0472","article-title":"Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720","volume":"26","author":"Baer","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib53","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib54","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a\u00a0randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib56","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bmt.2009.134","article-title":"5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation","volume":"45","author":"Field","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib57","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.bmt.1703028","article-title":"Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study","volume":"27","author":"Ravandi","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib58","first-page":"191","article-title":"Acetylation and histone deacetylase inhibitors in cancer","volume":"28","author":"Kortenhorst","year":"2006","journal-title":"Cell Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib59","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2174\/156802608784911581","article-title":"Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents","volume":"8","author":"Moradei","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bbmt.2010.05.005_bib60","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/annonc\/mdn792","article-title":"HDAC inhibitor-based therapies and haematological malignancy","volume":"20","author":"Stimson","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib61","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib62","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.05.005_bib63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib64","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib65","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1158\/1078-0432.CCR-04-1106","article-title":"Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant","volume":"10","author":"Stewart","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib66","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib67","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199810223391702","article-title":"Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype","volume":"339","author":"Aversa","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib68","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood-2007-06-093880","article-title":"T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin","volume":"110","author":"Jakubowski","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib69","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bmt.1705385","article-title":"Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath \u201cin the bag\u201d as T-cell depletion: the Leiden experience","volume":"37","author":"Barge","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib70","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bcmd.2007.07.015","article-title":"Enhancing T cell reconstitution after hematopoietic stem cell transplantation: a brief update of the latest trends","volume":"40","author":"Zakrzewski","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.bbmt.2010.05.005_bib71","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2008.02.010","article-title":"CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors","volume":"14","author":"Ge","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbmt.2007.10.002","article-title":"Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity","volume":"14","author":"Hartwig","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib73","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2006-04-014100","article-title":"Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines","volume":"109","author":"Wehler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib74","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0140-6736(02)09413-8","article-title":"Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1\/2 study","volume":"360","author":"Andre-Schmutz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.05.005_bib75","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2005-01-0393","article-title":"Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation","volume":"106","author":"Solomon","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib76","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib77","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1182\/blood-2009-06-204669","article-title":"Acute graft-versus-host disease; from the bench to the bedside","volume":"114","author":"Socie","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib78","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri2000","article-title":"Graft-versus-host disease","volume":"7","author":"Shlomchik","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib79","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.4049\/jimmunol.0802212","article-title":"Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia","volume":"182","author":"Zheng","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib80","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib81","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1126\/science.286.5441.958","article-title":"A direct estimate of the human alphabeta T cell receptor diversity","volume":"286","author":"Arstila","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2010.05.005_bib82","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","article-title":"Comprehensive assessment of T cell receptor {beta} chain diversity in {alpha}{beta} T cells","volume":"114","author":"Robins","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib83","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2009-05-222596","article-title":"Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self-\/nonself-recognition","volume":"114","author":"Rist","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib84","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.it.2008.02.005","article-title":"T-cell allorecognition: a case of mistaken identity or deja vu?","volume":"29","author":"Archbold","year":"2008","journal-title":"Trends Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib85","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc1365","article-title":"Molecules and mechanisms of the graft-versus-leukaemia effect","volume":"4","author":"Bleakley","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bbmt.2010.05.005_bib86","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1600-065X.2008.00660.x","article-title":"Negative signaling by inhibitory receptors: the NK cell paradigm","volume":"224","author":"Long","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.bbmt.2010.05.005_bib87","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bbmt.2009.01.019","article-title":"Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses","volume":"15","author":"Gill","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib88","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib89","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00262-008-0649-4","article-title":"TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008","volume":"58","author":"Uckert","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bbmt.2010.05.005_bib90","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib91","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","article-title":"A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS","volume":"113","author":"Keilholz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib92","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.05.005_bib93","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","article-title":"Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies","volume":"111","author":"Rezvani","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib94","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2008-05-155697","article-title":"Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation","volume":"113","author":"Jenq","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib95","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2010.05.005_bib96","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib97","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood-2005-08-3503","article-title":"Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation","volume":"107","author":"Berger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib98","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1182\/blood-2007-04-087346","article-title":"Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft","volume":"110","author":"Deschamps","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib99","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1182\/blood.V97.5.1249.h8001249_1249_1257","article-title":"A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease","volume":"97","author":"Thomis","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib100","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib101","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood-2003-08-2908","article-title":"Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model","volume":"103","author":"Berger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib102","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.4049\/jimmunol.175.3.1373","article-title":"Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity","volume":"175","author":"Rossi","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib103","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nature06175","article-title":"Taking dendritic cells into medicine","volume":"449","author":"Steinman","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2010.05.005_bib104","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/CJI.0b013e31818403bc","article-title":"Dendritic cells: a critical player in cancer therapy?","volume":"31","author":"Palucka","year":"2008","journal-title":"J Immunother"},{"key":"10.1016\/j.bbmt.2010.05.005_bib105","first-page":"6451","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine","volume":"61","author":"Banchereau","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib106","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.4049\/jimmunol.173.4.2780","volume":"173","author":"Ratzinger","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib107","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.immuni.2008.07.013","article-title":"Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells","volume":"29","author":"Klechevsky","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.bbmt.2010.05.005_bib108","unstructured":"Romano E, Rossi M, Ratzinger G, et\u00a0al. Human Langerhans cells stimulate robust cytolytic T-cells against tumor antigens, including WT1, by an IL15-dependent mechanism. Submitted."},{"key":"10.1016\/j.bbmt.2010.05.005_bib109","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood-2004-06-2492","article-title":"Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells","volume":"105","author":"Munz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib110","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.immuni.2007.08.015","article-title":"Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation","volume":"27","author":"Jiang","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.bbmt.2010.05.005_bib111","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1084\/jem.194.6.769","article-title":"Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo","volume":"194","author":"Hawiger","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib112","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1084\/jem.20021598","article-title":"Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class i products and peripheral CD8+ T cell tolerance","volume":"196","author":"Bonifaz","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib113","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.05.005_bib114","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2006-03-011353","article-title":"Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients","volume":"108","author":"Banerjee","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib115","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2008-11-191197","article-title":"Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells","volume":"114","author":"Chung","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib116","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1002\/eji.1830271209","article-title":"Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions","volume":"27","author":"Jonuleit","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib117","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/32183","article-title":"Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs","volume":"392","author":"Albert","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2010.05.005_bib118","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nature01911","article-title":"ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells","volume":"425","author":"Guermonprez","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2010.05.005_bib119","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/ni1147","article-title":"Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells","volume":"6","author":"Ackerman","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib120","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.4049\/jimmunol.171.11.5940","article-title":"Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 Melanoma","volume":"171","author":"Goldszmid","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib121","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nri2455","article-title":"Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells","volume":"8","author":"Merad","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib122","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2008-12-180646","article-title":"Dendritic cell homeostasis","volume":"113","author":"Merad","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib123","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood-2002-04-1093","article-title":"Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation","volume":"101","author":"Ratzinger","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib124","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V99.3.1071","article-title":"Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen","volume":"99","author":"Chakraverty","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib125","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.4049\/jimmunol.177.7.4414","article-title":"Host-derived langerhans cells persist after MHC-matched allografting independent of donor t cells and critically influence the alloresponses mediated by donor lymphocyte infusions","volume":"177","author":"Durakovic","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib126","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbmt.2007.08.052","article-title":"Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease","volume":"14","author":"Gomez-Almaguer","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1 Suppl. 1","key":"10.1016\/j.bbmt.2010.05.005_bib127","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbmt.2007.11.010","article-title":"Human polymorphism and variable outcomes of cancer chemotherapy and transplantation","volume":"14","author":"Davies","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib128","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.coi.2008.07.004","article-title":"Role of KIRs and KIR ligands in hematopoietic transplantation","volume":"20","author":"Velardi","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib129","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2008-09-177055","article-title":"Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation","volume":"113","author":"Yu","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib130","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V87.6.2195.bloodjournal8762195","article-title":"Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation","volume":"87","author":"Slavin","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib131","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib132","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib133","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.bmt.1703883","article-title":"Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions","volume":"31","author":"Raiola","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib134","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib135","first-page":"1214","article-title":"Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions","volume":"95","author":"Porter","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib136","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbmt.2003.10.004","article-title":"Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation","volume":"10","author":"Chiorean","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib137","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib138","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V95.1.67","article-title":"Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia","volume":"95","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib139","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbmt.2003.11.003","article-title":"Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease","volume":"10","author":"Posthuma","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib140","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bmt.1705167","article-title":"Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation","volume":"36","author":"Savani","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib141","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome","volume":"18","author":"Lokhorst","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib142","first-page":"609a","article-title":"CD6 T cell depleted allogeneic bone marrow transplant followed by CD4+ donor lymphocyte infusion for patients with multiple myeloma","volume":"94","author":"Alyea","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib143","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/bbmt.2003.50009","article-title":"Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity","volume":"9","author":"Peggs","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib144","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2004-05-2031","article-title":"Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma","volume":"104","author":"Kroger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib145","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib146","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood-2003-12-4321","article-title":"Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR","volume":"104","author":"Ritgen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib147","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusions of donor leukocytes to treat Epstein-Barr-associated lymphoproliferative disorders after allogeneic bone marrow transplantation","volume":"330","author":"Papadapoulos","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib148","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/hum.1994.5.3-381","article-title":"Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts","volume":"5","author":"Heslop","year":"1994","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.bbmt.2010.05.005_bib149","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib150","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V95.3.807.003k24_807_814","article-title":"Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells","volume":"95","author":"Gustafsson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib151","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.05.005_bib152","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2003-05-1513","article-title":"Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses","volume":"103","author":"Peggs","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib153","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2006-03-005769","article-title":"Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation","volume":"109","author":"Meyer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib154","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.smim.2003.12.003","article-title":"Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance","volume":"16","author":"Piccirillo","year":"2004","journal-title":"Semin Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.coi.2004.01.004","article-title":"Development and function of CD25+CD4+ regulatory T cells","volume":"16","author":"Fehervari","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib156","first-page":"4516","article-title":"Human CD4+ CD25+ regulatory T cells suppress NKT cell functions","volume":"63","author":"Azuma","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib157","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO;2-X","article-title":"CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells","volume":"30","author":"Cederbom","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib158","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1084\/jem.20021345","article-title":"CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms","volume":"197","author":"Maloy","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib159","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib160","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00262-008-0515-4","article-title":"Molecular mechanisms of MHC class I abnormalities and APM components in human tumors","volume":"57","author":"Seliger","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bbmt.2010.05.005_bib161","first-page":"5848","article-title":"The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos","volume":"11","author":"Ghattas","year":"1991","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib162","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bbmt.2010.05.005_bib163","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1173","article-title":"How T cells \u201csee\u201d antigen","volume":"6","author":"Krogsgaard","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib164","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1084\/jem.20031110","article-title":"Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer","volume":"199","author":"Heemskerk","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib165","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1002\/eji.200636539","article-title":"Designer T cells by T cell receptor replacement","volume":"36","author":"Sommermeyer","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib166","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1517\/14712598.5.5.627","article-title":"Development of 2A peptide-based strategies in the design of multicistronic vectors","volume":"5","author":"Szymczak","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.bbmt.2010.05.005_bib167","doi-asserted-by":"crossref","first-page":"8878","DOI":"10.1158\/0008-5472.CAN-06-1450","article-title":"Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR\/CD3 stability","volume":"66","author":"Cohen","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib168","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.clim.2005.12.009","article-title":"Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells","volume":"119","author":"Scholten","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib169","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.4049\/jimmunol.181.7.5128","article-title":"Requirements for effective antitumor responses of TCR transduced T cells","volume":"181","author":"de Witte","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib170","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1182\/blood-2007-02-075010","article-title":"Selecting highly affine and well-expressed TCRs for gene therapy of melanoma","volume":"110","author":"Jorritsma","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib171","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1385\/IR:34:1:67","article-title":"Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression","volume":"34","author":"Voss","year":"2006","journal-title":"Immunol Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib172","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.gt.3303078","article-title":"Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells","volume":"15","author":"Hart","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.bbmt.2010.05.005_bib173","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib174","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-05-023069","article-title":"Facilitating matched pairing and expression of TCR chains introduced into human T cells","volume":"109","author":"Kuball","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib175","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1158\/0008-5472.CAN-06-3986","article-title":"Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond","volume":"67","author":"Cohen","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib176","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4049\/jimmunol.180.1.391","article-title":"Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells","volume":"180","author":"Voss","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib177","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2141.2004.05077.x","article-title":"Human gammadelta T\u00a0cells as mediators of chimaeric-receptor redirected anti-tumour immunity","volume":"126","author":"Rischer","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib178","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/0008-5472.CAN-05-4190","article-title":"Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity","volume":"66","author":"van der Veken","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib179","first-page":"1001","article-title":"Cytolysis of tumor cells expressing the Neu\/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes","volume":"2","author":"Altenschmidt","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib180","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib181","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.05.005_bib182","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2010.05.005_bib183","doi-asserted-by":"crossref","first-page":"7739","DOI":"10.1073\/pnas.92.17.7739","article-title":"High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes","volume":"92","author":"Bunnell","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.05.005_bib184","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1089\/hum.1996.7.12-1415","article-title":"Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope","volume":"7","author":"Lam","year":"1996","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.bbmt.2010.05.005_bib185","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V90.3.952","article-title":"Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes","volume":"90","author":"Gallardo","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib186","doi-asserted-by":"crossref","first-page":"17372","DOI":"10.1073\/pnas.0608138103","article-title":"Gene transfer in humans using a conditionally replicating lentiviral vector","volume":"103","author":"Levine","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.05.005_bib187","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1128\/JVI.01812-07","article-title":"Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity","volume":"82","author":"Joseph","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib188","doi-asserted-by":"crossref","DOI":"10.1038\/gt.2008.90","article-title":"Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition","volume":"15","author":"Yang","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.bbmt.2010.05.005_bib189","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1084\/jem.189.11.1735","article-title":"Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes","volume":"189","author":"Unutmaz","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2003-01-0297","article-title":"Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence","volume":"102","author":"Cavalieri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib191","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood-2007-12-128751","article-title":"Resistance of mature T cells to oncogene transformation","volume":"112","author":"Newrzela","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib192","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib193","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/gt.2009.54","article-title":"Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity","volume":"16","author":"Peng","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/j.bbmt.2010.05.005_bib194","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood-2005-05-2133","article-title":"Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system","volume":"107","author":"Huang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymthe.2005.07.688","article-title":"High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation","volume":"13","author":"Zhao","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2010.05.005_bib196","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s00262-005-0098-2","article-title":"A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes","volume":"55","author":"Schaft","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bbmt.2010.05.005_bib197","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.05.005_bib198","doi-asserted-by":"crossref","first-page":"17469","DOI":"10.1073\/pnas.0907448106","article-title":"Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity","volume":"106","author":"Hinrichs","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.05.005_bib199","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2010.05.005_bib200","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1182\/blood-2008-12-192419","article-title":"Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination","volume":"114","author":"Klebanoff","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib201","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib202","first-page":"157","article-title":"Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras","volume":"119","author":"Papapetrou","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2010.05.005_bib203","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1158\/0008-5472.CAN-06-3977","article-title":"Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling","volume":"67","author":"Zhao","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib204","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/74455","article-title":"Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells","volume":"18","author":"Latouche","year":"2000","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib205","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2003-02-0345","article-title":"Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele","volume":"102","author":"Papanicolaou","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib206","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1158\/0008-5472.CAN-04-2991","article-title":"Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells","volume":"65","author":"Dupont","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib207","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2404329","article-title":"Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells","author":"Numbenjapon","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.05.005_bib208","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/mt.sj.6300134","article-title":"Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules","volume":"15","author":"Suhoski","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2010.05.005_bib209","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nbt0202-143","article-title":"Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB","volume":"20","author":"Maus","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib210","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.4049\/jimmunol.179.7.4910","article-title":"4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy","volume":"179","author":"Zhang","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib211","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nbt955","article-title":"The ABCs of artificial antigen presentation","volume":"22","author":"Kim","year":"2004","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib212","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.4049\/jimmunol.0804178","article-title":"A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy","volume":"183","author":"Hasan","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib213","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","article-title":"Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy","volume":"32","author":"Hollyman","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.bbmt.2010.05.005_bib214","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib215","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib216","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2010.05.005_bib217","series-title":"Marked Regression of Adenopathy follwoing Infusion of Autologous T Cells Genetically Targeted to the CD19 Antigen in a Patient with Bulky CLL","author":"Brentjens","year":"2010"},{"key":"10.1016\/j.bbmt.2010.05.005_bib218","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2010.05.005_bib219","doi-asserted-by":"crossref","first-page":"981e1","DOI":"10.1016\/j.ophtha.2008.12.004","article-title":"Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma","volume":"116","author":"Yeh","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bbmt.2010.05.005_bib220","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mt.2010.31","article-title":"Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial","volume":"18","author":"Brentjens","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2010.05.005_bib221","first-page":"3","article-title":"Immunological surveillance in neoplasia","volume":"7","author":"Burnet","year":"1971","journal-title":"Transplant Rev"},{"key":"10.1016\/j.bbmt.2010.05.005_bib222","first-page":"1129","article-title":"Rejection of lethal tumors after subcutaneous inoculation: a phenomenon of antigenic expression?","volume":"39","author":"Apffel","year":"1967","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2010.05.005_bib223","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1159\/000229954","article-title":"The role of the immune response in the establishment and rejection of neoplastic tissue","volume":"32","author":"Pollack","year":"1967","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib224","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1126\/science.146.3647.1055","article-title":"Antigens associated with a tumor virus: rejection of isogenic skin grafts from leukemic mice","volume":"146","author":"Breyere","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2010.05.005_bib225","first-page":"563","article-title":"Sex-linked rejection of normal and neoplastic tissue. I. Distribution and specificity","volume":"20","author":"Eichwald","year":"1958","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2010.05.005_bib226","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0167-5699(92)90198-G","article-title":"The immune system evolved to discriminate infectious nonself from noninfectious self","volume":"13","author":"Janeway","year":"1992","journal-title":"Immunol Today"},{"key":"10.1016\/j.bbmt.2010.05.005_bib227","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1126\/science.290.5489.11a","article-title":"Assessing the mechanisms that give rise to autoimmunity","volume":"290","author":"Zinkernagel","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2010.05.005_bib228","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood.V83.11.3377.3377","article-title":"Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor lymphocyte transfusions before the onset of hematological relapse","volume":"83","author":"van Rhee","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib229","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood.V86.11.4337.bloodjournal86114337","article-title":"CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation","volume":"86","author":"Giralt","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib230","first-page":"100","article-title":"Essai sur la prophylaxie du cancer","volume":"11","author":"Didot","year":"1851","journal-title":"Bull Acad R Belge"},{"key":"10.1016\/j.bbmt.2010.05.005_bib231","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/BF02982546","article-title":"Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction","volume":"74","author":"Deeg","year":"2001","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib232","first-page":"12","article-title":"Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant","volume":"4","author":"Porter","year":"1994","journal-title":"Transplant Sci"},{"key":"10.1016\/j.bbmt.2010.05.005_bib233","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/scd.1.1994.3.235","article-title":"Bone marrow transplantation in leukemia","volume":"3","author":"Rowlings","year":"1994","journal-title":"J Hematother"},{"key":"10.1016\/j.bbmt.2010.05.005_bib234","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1182\/blood.V86.10.3987.bloodjournal86103987","article-title":"Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia","volume":"86","author":"Hessner","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib235","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1056\/NEJMcibr045001","article-title":"Shedding light on immunotherapy for cancer","volume":"350","author":"Rosenberg","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib236","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bmt.1700778","article-title":"Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation","volume":"19","author":"Dermime","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.005_bib237","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1084\/jem.177.2.265","article-title":"Identification of human cancers deficient in antigen processing","volume":"177","author":"Restifo","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib238","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nm1381","article-title":"Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants","volume":"12","author":"van Hall","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib239","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI200316398","article-title":"Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells","volume":"111","author":"Molldrem","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2010.05.005_bib240","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00002371-199601000-00009","article-title":"Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy","volume":"19","author":"Rosenberg","year":"1996","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib241","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2010.05.005_bib242","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib243","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/1078-0432.CCR-07-1880","article-title":"Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine","volume":"14","author":"Welters","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib244","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1016\/j.vaccine.2005.04.049","article-title":"Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model","volume":"23","author":"Vambutas","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.bbmt.2010.05.005_bib245","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1084\/jem.134.6.1513","article-title":"Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice","volume":"134","author":"Cudkowicz","year":"1971","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib246","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2010.05.005_bib247","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1182\/blood-2002-04-1197","article-title":"Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor","volume":"100","author":"Davies","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib248","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.1995.tb03297.x","article-title":"Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells","volume":"89","author":"Dengler","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib249","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1126\/science.7539551","article-title":"Identification of a graft versus host disease-associated human minor histocompatibility antigen","volume":"268","author":"den Haan","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2010.05.005_bib250","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.193.2.195","article-title":"The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing","volume":"193","author":"Brickner","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib251","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.4049\/jimmunol.149.5.1788","article-title":"Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens","volume":"149","author":"de Bueger","year":"1992","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib252","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1084\/jem.189.2.301","article-title":"A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia","volume":"189","author":"Dolstra","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib253","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1073\/pnas.0530192100","article-title":"Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia","volume":"100","author":"Marijt","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.05.005_bib254","first-page":"5386","article-title":"Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1","volume":"55","author":"Hewitt","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib255","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0145-2126(99)00037-5","article-title":"Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF)","volume":"23","author":"Tsuboi","year":"1999","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib256","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood.V100.10.3835","article-title":"Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL","volume":"100","author":"Bellantuono","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib257","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2005-01-0146","article-title":"Elimination of human leukemia cells in NOD\/SCID mice by WT1-TCR gene-transduced human T cells","volume":"106","author":"Xue","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib258","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2004-09-3663","article-title":"Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes","volume":"106","author":"Tsuji","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib259","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.leu.2403186","article-title":"Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity","volume":"18","author":"Mailander","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.05.005_bib260","article-title":"Clinical and immune responses of WT1-peptide vaccination in patients with acute myeloid leukemia","author":"Keilholz","year":"2006","journal-title":"ASCO Annu Meet Proc"},{"key":"10.1016\/j.bbmt.2010.05.005_bib261","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2010.05.005_bib262","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1074\/jbc.271.6.2972","article-title":"Biosynthesis and processing of proteinase 3 in U937 cells. Processing pathways are distinct from those of cathepsin G","volume":"271","author":"Rao","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bbmt.2010.05.005_bib263","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/jlb.55.1.50","article-title":"Processing and intracellular transport of cathepsin G and neutrophil elastase in the leukemic myeloid cell line U-937-modulation by brefeldin A, ammonium chloride, and monensin","volume":"55","author":"Lindmark","year":"1994","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib264","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1046\/j.1523-1755.2000.00080.x","article-title":"Antiproteinase 3- and antimyeloperoxidase-associated vasculitis","volume":"57","author":"Franssen","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.bbmt.2010.05.005_bib265","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood.V89.10.3503","article-title":"Granules of the human neutrophilic polymorphonuclear leukocyte","volume":"89","author":"Borregaard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib266","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2249.1994.tb05511.x","article-title":"T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG)","volume":"98","author":"Brouwer","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib267","first-page":"2675","article-title":"A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia","volume":"59","author":"Molldrem","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.005_bib268","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/asheducation-2003.1.331","article-title":"Immunotherapy of hematologic malignancy","author":"Heslop","year":"2003","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2010.05.005_bib269","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood.V104.11.259.259","article-title":"Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia","volume":"104","author":"Qazilbash","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib270","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0378-1119(95)00398-P","article-title":"Characterization of the murine gene encoding the hyaluronan receptor RHAMM","volume":"163","author":"Entwistle","year":"1995","journal-title":"Gene"},{"key":"10.1016\/j.bbmt.2010.05.005_bib271","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0092-8674(95)90048-9","article-title":"Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation","volume":"82","author":"Hall","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.bbmt.2010.05.005_bib272","article-title":"RHAMM\/CD168-R3 Peptide vaccination of HLA-A2+ patients with acute myeloid leukemia(AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM)","author":"Greiner","year":"2005","journal-title":"Am Soc Hematol Annu Meet"},{"key":"10.1016\/j.bbmt.2010.05.005_bib273","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2004-12-4787","article-title":"Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM\/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia","volume":"106","author":"Greiner","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib274","first-page":"1324","article-title":"Synthetic peptide analogs derived from bcr\/abl fusion proteins and the induction of heteroclitic human T-cell responses","volume":"90","author":"Pinilla-Ibarz","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.05.005_bib275","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.05.005_bib276","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/0929867043456115","article-title":"Alpha-galactosylceramide: potential immunomodulatory activity and future application","volume":"11","author":"Hayakawa","year":"2004","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bbmt.2010.05.005_bib277","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.4049\/jimmunol.177.5.3484","article-title":"Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells","volume":"177","author":"Shimizu","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.05.005_bib278","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/sj.leu.2402943","article-title":"Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells","volume":"17","author":"Metelitsa","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.05.005_bib279","doi-asserted-by":"crossref","first-page":"15825","DOI":"10.1073\/pnas.0908358106","article-title":"Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation","volume":"106","author":"Ho","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.05.005_bib280","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood-2009-01-202606","article-title":"The leukemic stem cell niche: current concepts and therapeutic opportunities","volume":"114","author":"Lane","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.005_bib281","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/146532402320776099","article-title":"Immune therapy of AML","volume":"4","author":"Molldrem","year":"2002","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2010.05.005_bib282","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190801927510","article-title":"Immunotherapeutic approaches in chronic myelogenous leukemia","volume":"49","author":"Guilhot","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.05.005_bib283","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/sj.leu.2401486","article-title":"Cytosine demethylation of the proteinase-3\/myeloblastin primary granule protease gene during phagocyte development","volume":"13","author":"Lubbert","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.05.005_bib284","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/nm1310","article-title":"Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer","volume":"11","author":"Rapoport","year":"2005","journal-title":"Nat Med"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911000217X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911000217X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:36:50Z","timestamp":1761057410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911000217X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":284,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S108387911000217X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.05.005","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}